Navigation Links
Positive Results from Phase IIa Study Pave Way for Phase IIb Trial of DG051 for the Prevention of Heart Attack
Date:1/9/2008

REYKJAVIK, Iceland, Jan. 9 /PRNewswire-FirstCall/ -- deCODE genetics (Nasdaq: DCGN) today announced positive topline results from its Phase IIa clinical trial for DG051, the company's leukotriene A4 hydrolase inhibitor being developed for the prevention of heart attack. With these results, the company has finalized the design of a Phase IIb trial for which it expects to begin enrolling patients this spring. The company will discuss the development of DG051 and the rest of its product portfolio in its presentation at the JP Morgan 26th Annual Healthcare Conference. The presentation, to be delivered on Thursday January 10 at 11:30am PST/2:30pm EST/7:30pm GMT, will be webcast live via the investors' section of the company's website at http://www.decode.com.

In several studies conducted in healthy volunteers last year, DG051 was shown to reduce the production of leukotriene B4 (LTB4) in a dose-dependent manner. LTB4 is a pro-inflammatory molecule that deCODE's gene discovery and functional biology work identified as a one of the factors modulating risk of heart attack. The results of the double-blind, placebo-controlled Phase IIa study completed last month confirm that DG051 also delivers significant dose- dependent reductions in LTB4 in patients with a history of heart attack or coronary artery disease and who were taking a variety of concomitant medications. The pharmacokinetic and safety profiles of the compound were favorable and similar to those seen in previous studies in healthy volunteers. There were no serious adverse events in the study. The Phase IIb study, that will begin in the spring, will be a 400 patient, double-blind placebo- controlled study further examining its pharm
'/>"/>

SOURCE deCODE genetics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
3. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
4. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
5. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
6. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
7. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
8. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
9. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
10. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
11. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... DIEGO , Dec. 23, 2014 ResMed (NYSE: ... significant patent infringement action against Chinese medical device manufacturer BMC ... (ITC) ruled today that BMC,s masks listed below infringe ResMed,s ... or selling these masks in the United States ... iVolve N2 nasal mask , Willow nasal pillows mask ...
(Date:12/24/2014)... , Dec. 23, 2014   Synageva ... a biopharmaceutical company developing therapeutic products for rare ... Agency (EMA) of the Marketing Authorization Application (MAA) ... recently granted the company,s request for accelerated assessment, ... regulatory review time.   The MAA, ...
(Date:12/24/2014)...  Lockton Dunning Benefits, the Dallas ... addition of Vice President Kim Foerster ... Consulting team, Excelsior Solutions. Foerster ... the position.  Most recently, she worked as the ... Pharmacy, where she has held various managerial positions ...
Breaking Medicine Technology:ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3Kim Foerster Joins Lockton Companies 2
... DIEGO, Aug. 3, 2011 Proacta Incorporated and ... the expansion of their Collaborative Research, Development and ... a hypoxia-activated pro-drug for the treatment of cancer. ... parties agreed to expand their existing collaboration to ...
... Buehler Motor, Inc. ( http://www.buehlermotor.com ), a global ... challenging mechatronic drive solutions, today announced a partnership with ... of its DC/BLDC motor and gearmotor lines. ... South American medical equipment market, and introduce a new ...
Cached Medicine Technology:Proacta Incorporated and Yakult Honsha Announce Expansion of Their Collaborative Research, Development and Commercialization Agreement 2Proacta Incorporated and Yakult Honsha Announce Expansion of Their Collaborative Research, Development and Commercialization Agreement 3Buehler Motor Establishes Sales Partner in Brazil 2Buehler Motor Establishes Sales Partner in Brazil 3
(Date:12/25/2014)... “Every three months the trends for evening dresses ... be one of the hottest styles in the next few ... company releases 26 A-line sweetheart evening dresses, and announces the ... “We are trying our best to help a lady to ... with affordable prices, we provide discounted delivery costs to our ...
(Date:12/25/2014)... Angeles, CA (PRWEB) December 25, 2014 The ... Dolcemaschio was created in honor of a true 9/11 ... at two film festivals including the 24 hours of Nuremberg ... Festival in Bangladesh. , Actress, screenwriter and director ... helped produce this film together with her husband, Gregory ...
(Date:12/25/2014)... December 25, 2014 Helen Harris’ RP ... Woodland Hills, California after an 8 year battle with ... Christmas Eve evening in her home in Woodland Hills ... breast cancer. , As the founder ... years, she pioneered and championed many of today's greatest ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. ... chronic illnesses can receive effective, less expensive care from a ... to a team of dedicated health care professionals, a new ... ill and need either hospitalization or a trip to the ... home clinic at the University of Texas in Houston versus ...
(Date:12/25/2014)... (HealthDay News) -- Among early stage breast cancer patients ... of one percent will eventually develop leukemia as a ... The finding comes from a review of more than ... and it suggests that the risk for developing treatment-related ... previously thought. "The frequency of bone marrow cancers ...
Breaking Medicine News(10 mins):Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3
... technology developed at the University at Buffalo has killed ... including airborne spores, viruses and bacteria in independent tests ... A prototype produced by Buffalo BioBlower Technologies LLC, a ... of better than one part per million in an ...
... Removal of Toxic Mercury,from Vaccines, NIXA, Mo., ... (ACIP) recommended yesterday that flu shots be,administered annually ... age. ACIP,functioning under the Centers for Disease Control ... by parents of vaccine-injured,children for neglecting vaccine safety ...
... PAULO, Brazil, Feb. 28 Medial Saude S/A,(BOVESPA: MEDI3) (MEDIAL SAUDE) announces the ... Quarter 2007 Earnings Conference Call, When: Thursday, March ... , How: Live over the Internet -- ... address above., Conference call dial-in phone ...
... European Commission Director General for Enterprise & Industry Heinz Zourek ... of an EC budget of 624 million to ESA as ... (GSC). , This will be provided in two stages: 419 ... of the GSC programme. Segment 2 will be submitted for ...
... Allscripts-Led Initiative Works With Google Health to Enable ... Collaboration between ... Direct from the 2008,HIMSS Exhibition and Conference, ... information solutions that physicians,use to improve healthcare, announced ...
... North Carolina State University have found that humans and ... also share the same genetic basis for certain types ... of the way the genomes have evolved, getting cancer ... Jaime Modiano, V.M.D., Ph.D., University of Minnesota College of ...
Cached Medicine News:Health News:UB's bioblower closer to protecting soldiers from biological attack 2Health News:UB's bioblower closer to protecting soldiers from biological attack 3Health News:CDC Vaccine Committee Recommends More Shots for Children 2Health News:Space sentinels: New 'tools' in space to improve European environment and security policies 2Health News:Space sentinels: New 'tools' in space to improve European environment and security policies 3Health News:The National ePrescribing Patient Safety Initiative Collaborates With Google 2Health News:The National ePrescribing Patient Safety Initiative Collaborates With Google 3Health News:The National ePrescribing Patient Safety Initiative Collaborates With Google 4Health News:U of Minn researchers discover genetic cancer link between humans and dogs 2Health News:U of Minn researchers discover genetic cancer link between humans and dogs 3
Myoglobin EIA Lipid / Protein Quantification, Cardiovascular 024-IDC-13 Muscle Disease...
Human Growth Hormone EIA Endocrine Function 025-BC-1033...
... hormone responsible for the control of glucose metabolism. ... the islets of Langerhans as the precursor, proinsulin, ... Both are secreted in equimolar amounts into ... is comprised of two polypeptide chains, the A-chain ...
Intact PTH EIA Bone and Mineral Metabolism 021-SDX016 Parathyroid Hormone...
Medicine Products: